Can Large Language Models Reliably Interpret Radiology Reports? A Systematic Evaluation for Tumor Progression Classification

Valentin Pohyer(Hôpital Européen Georges-Pompidou), Bastien Rance(Inserm), Loïc Duron(Inserm), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Laetitia Perronne(Université Paris Cité), Constance de Margerie‐Mellon(Université Paris Cité), Laure Fournier(Inserm), Constance Thibault(Hôpital Européen Georges-Pompidou)

Research Square

September 23, 2025

10.21203/rs.3.rs-7630430/v1

Cited by 0

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

|Nature|2021|603

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

|Cell|2018|565

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2021|411